Advances in Breast Cancer Research

Vol.2 No.4(2013), Paper ID 36732, 8 pages

DOI:10.4236/abcr.2013.24022

 

Subcutaneous Trastuzumab (Herceptin®): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer

 

Russell Burcombe, Steve Chan, Richard Simcock, Kunal Samanta, Fran Percival, Peter Barrett-Lee

 

Maidstone and Tunbridge Wells NHS Trust, Maidstone, UK
Nottingham University Hospitals NHS Trust, Nottingham, UK
Brighton and Sussex University Hospitals NHS Trust, Brighton, UK
Roche Products Ltd., Welwyn Garden City, UK
pH Associates Ltd., Marlow, UK
Velindre Cancer Centre, Cardiff, UK

 

Copyright © 2013 Russell Burcombe, Steve Chan, Richard Simcock, Kunal Samanta, Fran Percival, Peter Barrett-Lee et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

 

How to Cite this Article


Burcombe, R. , Chan, S. , Simcock, R. , Samanta, K. , Percival, F. and Barrett-Lee, P. (2013) Subcutaneous Trastuzumab (Herceptin®): A UK Time and Motion Study in Comparison with Intravenous Formulation for the Treatment of Patients with HER2-Positive Early Breast Cancer. Advances in Breast Cancer Research, 2, 133-140. doi: 10.4236/abcr.2013.24022.

Copyright © 2020 by authors and Scientific Research Publishing Inc.

Creative Commons License

This work and the related PDF file are licensed under a Creative Commons Attribution 4.0 International License.